Meta AnalysisID 1560
10天与14天含铋剂四联疗法根除幽门螺杆菌的系统评价与Meta分析
CRD42022295372
Is a 10-day course of bismuth-containing quadruple therapy to eradicate Helicobacter pylori equivalent to a 14-day course of treatment? Are the adverse reactions of the 10-day treatment course of bismuth-containing quadr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1560
- Evidence Id
- 10118
- Core Evidence Id
- 10118
- Source Meta Analysis Id
- 1514
- Herb2 Meta Analysis Id
- HBMA001514
- Crd Id
- CRD42022295372
- Title
- Systematic Review and Meta-analysis of 10 and 14 days Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
- Review Question
- Is a 10-day course of bismuth-containing quadruple therapy to eradicate Helicobacter pylori equivalent to a 14-day course of treatment? Are the adverse reactions of the 10-day treatment course of bismuth-containing quadruple therapy less than that of the 14-day treatment course? A systematic review and Meta analysis of Randomized Controlled trials.
- Study Type Included
- We considered only parallel group randomised controlled trials (RCTs) eligible for inclusion in the review.
- Condition Being Studied
- Helicobacter pylori (H.pylori) infection is a common global infectious disease and an important cause of diseases such as duodenal ulcer, gastric ulcer, gastric adenocarcinoma and gastric lymphoma. Because Helicobacter pylori was a notable cause of gastric cancer development, it should be eradicated to prevent gastric cancer. In 2015, the estimated prevalence of H. pylori in China was 55.8%. Amoxicillin-containing bismuth quadruple therapy for 14 days is the main eradication program recommended by the current guidelines. Guidelines for the management of Helicobacter pylori infection in Japan recommend a 1-week triple therapy consisting of potassium-competitive acid blocker (P-CAB), amoxicillin, and clarithromycin. Mass eradication of Helicobacter pylori has been proposed as a means to eliminate gastric cancer, And indeed reduced gastric cancer incidence with no increase in the likelihood of adverse consequences. However, Economic models have suggested that population screening and treatment for Helicobacter pylori may be cost-effective and may be the first cost-neutral screening program. If the cost of treatment can be further reduced, the benefit-cost ratio of large-scale screening for Helicobacter pylori may be improved.
- Participant
- Inclusion criteria: 1. Parallel group randomised controlled trials (RCTs) 2. Trials containing bismuth‐based quadruple therapy regimen (PPI bismuth‐based quadruple therapy: PPI + bismuth salt (colloidal bismuth subcitrate (CBS) or bismuth subsalicylate (BSS)) + two antibiotics.)； 2. Writing in English； 3. recruited individuals diagnosed as positive for H. pylori, with at least one confirmatory test, on the basis of a rapid urease test (RUT), histology or culture of an endoscopic biopsy sample, urea breath test (UBT), or monoclonal stool antigen tests (HpSA), regardless of the presenting symptoms and disease. 4. The participants must have been adults (aged 18 years or over). If the study did not specify it was for paediatric patients and we could not obtain additional data from authors, we judged that the majority of the study participants were adults, based on the following a priori criteria. 5. Reporting intention to treat (ITT). 6. Eradication assessments at least 4 weeks after completion of treatment. Excluded criteria: 1. Trials with participants who had previously been treated with an eradication therapy; 2. Reviews, case reports, editorials, letter to the editors, and abstracts from conferences. Duplicate papers or evaluating the same sample. 3. Studies without full-text report.
- Animal
- Human Disease Modelled
- Intervention
- A 10-day course of PPI bismuth‐based quadruple Helicobacter pylori eradication treatment. (PPI bismuth‐based quadruple therapy: PPI + bismuth salt (colloidal bismuth subcitrate (CBS) or bismuth subsalicylate (BSS)) + two antibiotics.)
- Comparator Control
- A 14-day course of PPI bismuth‐based quadruple Helicobacter pylori eradication treatment. (PPI bismuth‐based quadruple therapy: PPI + bismuth salt (colloidal bismuth subcitrate (CBS) or bismuth subsalicylate (BSS)) + two antibiotics.)
- Main Outcome
- The eradication rate of 14 versus 7 days of different regimens in eradicating H. pylori. (Eradication rate: The percentage of successful eradication of all participants.) Measures of effect relative risks
- Outcome Measure
- Additional Outcome
- The incidence of adverse effects associated with different durations of H. pylori eradication therapy.（adverse effects: the proportion of all participants who have an adverse reaction.） Measures of effect relative risks
- Study Method
- Systematic review
- Keyword
- Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans
- Contact
- XIULI ZUO [email protected]
- Organisational Affiliation
- Shandong University
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-06
- Registration Date
- 2022-01-06
- Anticipated Start Date
- 2021-12-26
- Anticipated Completion Date
- 2022-01-31
- Title Cn
- 10天与14天含铋剂四联疗法根除幽门螺杆菌的系统评价与Meta分析
- Title En
- Systematic Review and Meta-analysis of 10 and 14 days Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
- Bilingual Status
- complete